Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...